Prilosec Rx-to-OTC switch
Executive Summary
AstraZeneca/Proctor & Gamble's Prilosec (omeprazole) prescription to over-the-counter application for prevention of symptoms of frequent heartburn will be reviewed by FDA's Nonprescription Drugs and Gastrointestinal Drugs Advisory Committees June 21. The committees previously voted against a switch for episodic treatment of heartburn but left the prevention claim open (1"The Pink Sheet" Oct. 23, 2000, p. 24). The revised application is for once-daily 20 mg for 14 days. The meeting will be held at the Holiday Inn in Bethesda, Md. at 8 a.m. (Sign up for a webcast at 2FDAAdvisoryCommittee.com)...
You may also be interested in...
Prilosec GERD Indication Suitability For OTC Use Debated By Advisory Cmte.
Gastroesophageal reflux disease is appropriate for OTC treatment, but AstraZeneca/Procter & Gamble's NDA to switch Prilosec OTC is not approvable, FDA's Nonprescription and Gastrointestinal Drugs Advisory Committees voted at a joint meeting Oct. 20.
At-Home Health Testing Demand Is High Post-Pandemic, But So Are Barriers To Development And Use
At the recent Precision Med-Tri Con conference, laboratory experts traded views on the expansion of at-home testing for disease diagnosis and personalized health insights. While strong consumer demand spells opportunity, there are significant concerns about the accuracy and reliability of home-testing platforms, misuse, accessibility, and lack of health literacy.
Simplified Clinical Trial Transparency Rules To Go Live In The EU In June
A new version of the EU Clinical Trials Information System’s public portal will integrate the functionalities of the streamlined transparency rules.